Factor Xa inhibitors: all 607 studies that test it
Page 4 of 7. Open to participants first (111), then studies with results posted, then the rest; newest registration first within each.
- Apixaban Prevents Portal Vein Thrombosis After Laparoscopic Splenectomy and Azygoportal DisconnectionCompletedNCT05304455Not applicable
- Chemoprophylaxis With Rivaroxaban for Lower Limb Deep Vein Thrombosis in Colorectal CancerStatus unknownNCT05303818Phase 4
- Cost-effectiveness Analysis Between Two Anticoagulation Strategies for Atrial Fibrillation in the Postoperative Period of Coronary Artery Bypass Graft SurgeryStatus unknownNCT05300555Phase 4
- Antithrombotic Therapy in Acute Coronary Syndromes and Coronary Artery EctasiaStatus unknownNCT05233124Phase 2
- Trained Immunity by Dual-pathway Inhibition in Coronary Artery DiseaseStatus unknownNCT05210725Phase 4
- Apixaban in Patients With Left Ventricular ThrombusCompletedNCT05208398Phase 3
- A Study to Compare Pharmacokinetic Parameters and Safety Profiles Between AD-109 and AD-1091CompletedNCT05128591Phase 1
- Effects of Edoxaban on Platelet AggregationCompletedNCT05122455Phase 2/3
- Efficacy and Safety of Apixaban in COVID-19 Coagulopathy Patients With Respiratory Severity Under Critical CareStatus unknownNCT05088928Phase 2
- Direct Oral Anticoagulants for Prevention of lEft ventRIcular Thrombus After Anterior Acute Myocardial InFarction - APERITIFCompletedNCT05077683Phase 3
- Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular AtherostenosisActive, not recruitingNCT05047172Phase 3
- AntiCoagulation Versus AcetylSalicylic Acid After Transcatheter Aortic Valve ImplantationCompletedNCT05035277Phase 3
- THromboprophylaxis In Sickle Cell Disease With Central Venous Catheters (THIS)TerminatedNCT05033314Phase 3
- The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery DiseaseCompletedNCT05009862Phase 4
- Endovenous Laser Ablation in Acute Thrombophlebitis of the Varicose Great Saphenous VeinCompletedNCT05001776Phase 4
- Venous Thromboembolism Prophylaxis After Gynecological Pelvic Cancer Surgery With Rivaroxaban vs EnoxaparinStatus unknownNCT04999176Phase 3
- Effectiveness of Combined Anticoagulation and Antithrombotic Therapy vs Antithrombotic Therapy Alone After Lower Extremity Revascularization for Peripheral Arterial DiseaseStatus unknownNCT04994223Early Phase 1
- Rivaroxaban in Left Ventricular ThrombusCompletedNCT04970576Phase 4
- Prophylactic vs Therapeutic Anticoagulation in Symptomatic Isolated Distal Deep Vein ThrombosisStatus unknownNCT04967573Phase 3
- Restart TICrH Alpha Pilot Protocol, Restarting DOACs After Traumatic Intracranial HemorrhageStatus unknownNCT04891861Phase 3
- Rivaroxaban 2.5 mg BID and Aspirin for Intermittent Claudication in PAD PatientsCompletedNCT04853719Phase 4
- Causes and Prevention of Thromboembolic Disease in Nephrotic SyndromeCompletedNCT04850378Phase 1/2
- Rivaroxaban in Type 2 Myocardial InfarctionsCompletedNCT04838808Phase 2/3
- Rivaroxaban or Aspirin in Patients With CHD & GD Undergoing PCIStatus unknownNCT04805710Phase 4
- HElping Alleviate the Longer-term Consequences of COVID-19 (HEAL-COVID)Status unknownNCT04801940Phase 3
- Non Inferiority Study of a Reduced Dose of Activated Charcoal on Rivaroxaban Pharmacokinetics.CompletedNCT04767776Phase 1
- COVID-19 Antithrombotic Rivaroxaban EvaluationTerminatedNCT04757857Phase 4
- Bioequivalence Study of Two Formulations of Rivaroxaban Tablets 10 mg in Healthy Male Volunteers in Fasting ConditionsStatus unknownNCT04753489Phase 1
- Apixaban for PrOphyLaxis of thromboemboLic Outcomes in COVID-19TerminatedNCT04746339Phase 4
- Clinical Trial to Investigate Safety and Efficacy of Edoxaban in Patients With CTEPH (KABUKI)CompletedNCT04730037Phase 3
- Bioequivalence Study of Two Formulations of Rivaroxaban Tablets 20 mg in Healthy Male Volunteers Under Fed ConditionsStatus unknownNCT04729998Phase 1
- A Trial to Learn How Much Rivaroxaban Gets Into the Blood When Taken in Different Forms and How Safe They Are in Healthy MenCompletedNCT04727021Phase 1
- A Trial to Learn How a New Liquid Form of Rivaroxaban Behaves and How Safe it is Compared to the Current Tablet Form of Rivaroxaban in Healthy Male ParticipantsCompletedNCT04720092Phase 1
- Safety and Efficacy of Doxycycline and Rivaroxaban in COVID-19Status unknownNCT04715295Phase 4
- Effects of APIXaban on BRAIN Protection in Patients With Sinus Rhythm and Heart Failure: APIXBRAIN-HF TrialStatus unknownNCT04696120Phase 2
- Bioequivalence of Xaroban 20mg (Rivaroxaban) Tablet and Xarelto 20mg (Rivaroxaban) Tablet Under Fed ConditionsCompletedNCT04689919Phase 1
- Medically Ill Hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis With Rivaroxaban ThErapy: The MICHELLE TrialCompletedNCT04662684Phase 3
- Apixaban, Warfarin and Aspirin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy（ESAWAAPT）CompletedNCT04645550Phase 4
- Factor Xa Inhibitor Versus Standard of Care Heparin in Hospitalized Patients With COVID-19 (XACT)CompletedNCT04640181Phase 2
- Rivaroxaban vs. Warfarin in CVT TreatmentCompletedNCT04569279Phase 3
- CorONa Virus edoxabaN ColchicinE (CONVINCE) COVID-19TerminatedNCT04516941Phase 3
- FREEDOM COVID-19 Anticoagulation StrategyCompletedNCT04512079Phase 4
- Apixaban for Prevention of Post-angioplasty Thrombosis of Hemodialysis Vascular AccessStatus unknownNCT04489849Phase 4
- Postoperative Thrombosis Prevention in Patients With CDActive, not recruitingNCT04486859Not applicable
- Efficacy of Apixaban in Malignancy With Deep Venous ThrombosisStatus unknownNCT04462003Phase 3
- Safety of Fondaparinux as Post Partum ThromboprophylaxisCompletedNCT04447378Phase 4
- Pharmacokinetics and Bioequivalence of Rivaroxaban Tablet in Healthy Chinese VolunteersCompletedNCT04424381Phase 1
- Effect of Anticoagulation Therapy on Clinical Outcomes in COVID-19TerminatedNCT04416048Phase 2
- Anticoagulation Therapy After Splenectomy in Cirrhosis PatientCompletedNCT04397289Phase 1/2
- Full Anticoagulation Versus Prophylaxis in COVID-19: COALIZAO ACTION TrialCompletedNCT04394377Phase 4
- Enhanced Platelet Inhibition in Critically Ill Patients With COVID-19CompletedNCT04368377Phase 2
- Austrian CoronaVirus Adaptive Clinical Trial (COVID-19)Status unknownNCT04351724Phase 2/3
- Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial.TerminatedNCT04333407Not applicable
- Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) TrialCompletedNCT04324463Phase 3
- Rivaroxaban for Thromboprophylaxis in High-risk Cancer Patients With Totally Implantable Access PortsStatus unknownNCT04309240Phase 3
- A Prospective Multi-dose Study of Apixaban in Subjects With Nephrotic SyndromeCompletedNCT04278729Phase 1
- Rivaroxaban Plus ASA in Embolic Stroke of Undetermined Source(AREST-ESUS)CompletedNCT04273516Phase 2/3
- Prophylactic Anticoagulation for Catheter-related ThrombosisStatus unknownNCT04256525Phase 4
- Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm PatientsCompletedNCT04243122Phase 2
- Efficacy and Safety of Apixaban in Reducing Restenosis and Limb Loss in PAD Patients.Status unknownNCT04229264Phase 3
- DUAL Pathway Inhibition to Improve Endothelial Function in Peripheral Artery DiseaseCompletedNCT04218656Phase 4
- Pharmacokinetics of Apixaban in Patients Undergoing PancreaticoduodenectomyCompletedNCT04191928Phase 1
- Pharmacokinetics of Rivaroxaban After Bariatric SurgeryCompletedNCT04180436Phase 1
- Rotterdam EDOXaban Leaflet Evaluation in Patients After Transcatheter Aortic Valve ImplantationStatus unknownNCT04171726Phase 3
- Deep Vein Thrombosis Prophylaxis Adherence: Enoxaparin vs RivaroxabanStatus unknownNCT04169269Phase 4
- Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in Intracranial Atherosclerotic DiseaseCompletedNCT04142125Phase 3
- Clinical Outcomes Between Anticoagulation and DAPT Therapy in AF Patients Successfully Undergoing LAAOStatus unknownNCT04135677Phase 4
- A Prospective Study in Chinese Patients With Lower Extremity Ankle Fracture of Oral Anticoagulants to Prevent Venous Thromboembolism (VTE)Status unknownNCT04128254Phase 4
- Safety and Efficacy of Edoxaban in Thoracoscopic AblationCompletedNCT04121767Not applicable
- Prophylaxis With Apixaban in Transplant Eligible Patients With Multiple Myeloma Receiving Induction Therapy With IMiDsTerminatedNCT04106700Phase 2
- AntiCoagulants and COGnitionStatus unknownNCT04073316Phase 4
- Study on Impact of Edoxaban Treatment in Cancer Patients With Venous Thromboembolism During Antineoplastic TherapyCompletedNCT04072068Phase 4
- Synergistic Influence of Rivaroxaban on Inflammation and Coagulation Biomarkers in Patients With CAD and PAD on Aspirin TherapyStatus unknownNCT04059679Phase 4
- Oral Anticoagulant Apixaban for Treatment of Venous ThromboembolismCompletedNCT04041843Phase 2
- Drug Interaction Study of Apixaban With Cyclosporine or Tacrolimus in Transplant RecipientsCompletedNCT04023760Phase 4
- Apixaban for Intrahepatic Non Cirrhotic Portal HypertensionActive, not recruitingNCT04007289Phase 3
- DOAC Versus VKA After Cardiac SurgeryWithdrawnNCT04002011Phase 2
- PREvention of STroke in Intracerebral haemorrhaGE Survivors With Atrial FibrillationCompletedNCT03996772Phase 3
- Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney DiseaseCompletedNCT03969953Phase 3
- EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF)CompletedNCT03950076Phase 4
- Comparative Study of Oral Anticoagulation in Left Ventricular ThrombiCompletedNCT03926780Phase 3
- RIvoraxaban in Mitral StenosisTerminatedNCT03926156Phase 3
- Resolution of Thrombi in Left Atrial Appendage With EdoxabanCompletedNCT03840291Phase 4
- Oral Anticoagulation in HemodialysisCompletedNCT03799822Phase 4
- A Trial of Rivaroxaban Versus Warfarin in Dissolving Left Atrial Appendage Thrombus in Patients With Atrial FibrillationStatus unknownNCT03792152Not applicable
- Prevention of Post-STEMI Left Ventricular Thrombus With Optimized Anticoagulant (EARLYmyo-LVT Ⅱ)Status unknownNCT03786757Phase 3
- Can Very Low Dose Rivaroxaban in Addition to Dual Antiplatelet Therapy (DAPT) Improve Thrombotic Status in Acute Coronray Syndrome (ACS) ACSStatus unknownNCT03775746Phase 4
- Treatment of Post-STEMI Left Ventricular Thrombus With Optimized AnticoagulantStatus unknownNCT03764241Phase 3
- Early Rivaroxaban for Acute Ischemic Stroke or TIA Patients With Atrial FibrillationCompletedNCT03749057Phase 4
- Efficacy Comparison of Warfarin Versus Rivaroxaban CVTStatus unknownNCT03747081Phase 1/2
- Edoxaban Versus Edoxaban With antiPlatelet Agent In Patients With Atrial Fibrillation and Chronic Stable Coronary Artery DiseaseCompletedNCT03718559Phase 4
- API-CAT STUDY for APIxaban Cancer Associated ThrombosisCompletedNCT03692065Phase 3
- RIvaroxaban for Stroke Patients With AntiPhospholipid SyndromeCompletedNCT03684564Phase 2
- Apixaban for Extended Anticoagulation (APIDULCIS)TerminatedNCT03678506Phase 4
- Efficacy and Safety of Rivaroxiban Compare With Vitamin K Antagonist WarfarinWithdrawnNCT03673605Phase 4
- NOAC Plasma Concentration and Blood Coagulation in Healthy VolunteersCompletedNCT03666650Phase 4
- Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery OcclusionTerminatedNCT03630055Phase 3
- Surgical Revascularization Outcomes After Oral Anticoagulation or AntiplateletsStatus unknownNCT03605433Phase 3
- Edoxaban for the Treatment of Coagulopathy in Patients With Active Cancer and Acute Ischemic Stroke: a Pilot Study. (ENCHASE Study)Status unknownNCT03570281Phase 2/3
- Rivaroxaban vs Warfarin in Patients With Metallic ProsthesisTerminatedNCT03566303Phase 2/3